Your browser doesn't support javascript.
loading
Quantitative Brain Amyloid PET.
Jagust, William J; Mattay, Venkata S; Krainak, Daniel M; Wang, Sue-Jane; Weidner, Lora D; Hofling, A Alex; Koo, Hayoung; Hsieh, Pamela; Kuo, Phillip H; Farrar, Gill; Marzella, Libero.
Afiliación
  • Jagust WJ; University of California, Berkeley, California.
  • Mattay VS; Division of Imaging and Radiation Medicine, Office of Specialty Medicine, Office of New Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland; venkata.mattay@fda.hhs.gov.
  • Krainak DM; Division of Radiological Imaging and Radiation Therapy Devices, Office of Radiological Health, Office of Product Evaluation and Quality, Centers for Devices and Radiological Health, Food and Drug Administration, Silver Spring, Maryland.
  • Wang SJ; Division of Biometrics I, Office of Biostatistics, Office of Translational Sciences, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
  • Weidner LD; Division of Radiological Imaging and Radiation Therapy Devices, Office of Radiological Health, Office of Product Evaluation and Quality, Centers for Devices and Radiological Health, Food and Drug Administration, Silver Spring, Maryland.
  • Hofling AA; Division of Imaging and Radiation Medicine, Office of Specialty Medicine, Office of New Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
  • Koo H; Division of Imaging and Radiation Medicine, Office of Specialty Medicine, Office of New Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
  • Hsieh P; DRT Strategies, Arlington, Virginia.
  • Kuo PH; University of Arizona, Tucson, Arizona; and.
  • Farrar G; GE Healthcare, Amersham, United Kingdom.
  • Marzella L; Division of Imaging and Radiation Medicine, Office of Specialty Medicine, Office of New Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
J Nucl Med ; 65(5): 670-678, 2024 May 01.
Article en En | MEDLINE | ID: mdl-38514082
ABSTRACT
Since the development of amyloid tracers for PET imaging, there has been interest in quantifying amyloid burden in the brains of patients with Alzheimer disease. Quantitative amyloid PET imaging is poised to become a valuable approach in disease staging, theranostics, monitoring, and as an outcome measure for interventional studies. Yet, there are significant challenges and hurdles to overcome before it can be implemented into widespread clinical practice. On November 17, 2022, the U.S. Food and Drug Administration, Society of Nuclear Medicine and Molecular Imaging, and Medical Imaging and Technology Alliance cosponsored a public workshop comprising experts from academia, industry, and government agencies to discuss the role of quantitative brain amyloid PET imaging in staging, prognosis, and longitudinal assessment of Alzheimer disease. The workshop discussed a range of topics, including available radiopharmaceuticals for amyloid imaging; the methodology, metrics, and analytic validity of quantitative amyloid PET imaging; its use in disease staging, prognosis, and monitoring of progression; and challenges facing the field. This report provides a high-level summary of the presentations and the discussion.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Encéfalo / Tomografía de Emisión de Positrones / Amiloide Límite: Humans Idioma: En Revista: J Nucl Med Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Encéfalo / Tomografía de Emisión de Positrones / Amiloide Límite: Humans Idioma: En Revista: J Nucl Med Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos